SCHEMBL1011111

SCHEMBL1011111

CC(C)(C)OC(=O)N1C2CCC1CC(Oc1ccc3ccc(=O)oc3c1)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.47
KDM4E B2RXH2 8/20 0.46
ALDH1A1 P00352 6/20 0.46
GLA P06280 4/20 0.46
GAA P10253 4/20 0.46
HPGD P15428 4/20 0.46
MAPT P10636 2/20 0.46
HIF1A Q16665 1/20 0.46
CA12 O43570 4/20 0.44
CA9 Q16790 4/20 0.44
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 3/20 0.43
TSHR P16473 1/20 0.43
CA1 P00915 3/20 0.43
CA4 P22748 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1949495 0.96 MAOA (0.47) MAOAKDM4EALDH1A1GLAGAA
SCHEMBL1949494 0.96 MAOA (0.47) MAOAKDM4EALDH1A1GLAGAA
SCHEMBL1091721 0.93 CA12 (0.46) MAOAKDM4EALDH1A1GLAGAA
SCHEMBL4438932 0.92 KDM4E (0.42) MAOAKDM4EALDH1A1GLAGAA
SCHEMBL741083 0.87 SLC6A2 (0.48) MAOAALDH1A1HPGDCHRM2CHRM1
SCHEMBL741084 0.87 SLC6A2 (0.48) MAOAALDH1A1HPGDCHRM2CHRM1
SCHEMBL15304583 0.87 SLC6A2 (0.48) MAOAALDH1A1HPGDCHRM2CHRM1
SCHEMBL3183936 0.86 MAOB (0.44) MAOAKDM4EALDH1A1HPGDCHRM2
SCHEMBL1091835 0.86 MAOB (0.44) MAOACHRM2CHRM1CHRM3GPR119
SCHEMBL1091288 0.86 MAOB (0.44) MAOAKDM4EALDH1A1HPGDCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410271-B2 exo-7-(8-H-8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one; mood disorder, depression, dysthymic disorder, bipolar disorder, cyclothymic disorder; sleep disorders; psychological disorders NEUROSEARCH A/S (DK) 2013-04-02 US disclosed
US-8263617-B2 Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2012-09-11 US disclosed
EP-1989202-B1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2012-07-25 EP disclosed
US-8153797-B2 Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2012-04-10 US disclosed
EP-2311835-A1 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NeuroSearch AS (DK) 2011-04-20 EP disclosed
EP-2284170-A1 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NeuroSearch AS (DK) 2011-02-16 EP disclosed
EP-1797088-B1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2011-01-05 EP disclosed
EP-2121677-B1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-03 EP disclosed
EP-2121678-B1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-03 EP disclosed
US-20100227883-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS ANIONA APS (DK) 2010-09-09 US disclosed
US-20100056562-A1 CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2010-03-04 US disclosed
US-20100029711-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEURO SEARCH A/S (DK) 2010-02-04 US disclosed
US-20090312364-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2009-12-17 US disclosed
EP-2121678-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2009-11-25 EP disclosed
EP-2121677-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2009-11-25 EP disclosed
EP-1989202-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-11-12 EP disclosed
WO-2008074798-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed
WO-2008074797-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed
US-20070232666-A1 Novel Chromen-2-One Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors INITIATOR PHARMA A/S (DK) 2007-10-04 US disclosed
WO-2007093604-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029711-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC18A1, SLC6A2 MAOA 6/4885KDM4E 1365/4885ALDH1A1 676/4885
US-20090312364-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC6A2, SLC18A2, SLC18A1 MAOA 7/4885KDM4E 1135/4885ALDH1A1 1001/4885
US-20070232666-A1 Novel Chromen-2-One Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC6A2, SLC18A2, SLC18A1 MAOA 7/4885KDM4E 1135/4885ALDH1A1 1001/4885
US-20100227883-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC6A2, SLC18A2, SLC18A1 MAOA 7/4885KDM4E 1135/4885ALDH1A1 1001/4885
US-20100056562-A1 CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC6A2, SLC18A2, SLC18A1 MAOA 5/4885KDM4E 974/4885ALDH1A1 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.